Skip to product information
1 of 1

TAK1 Recombinant Rabbit mAb (S-6525)

TAK1 Recombinant Rabbit mAb (S-6525)

Catalog Number: S0B60827 Application: WB Reactivity: Hu Conjugation: Unconjugated Brand: Starter
Price:
Regular price $100 USD
Regular price Sale price $100 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rabbit
Antigen TAK1
Location Nucleus
Accession P49116
Clone Number S-6525
Antibody Type Recombinant mAb
Isotype IgG
Application WB
Reactivity Hu
Positive Sample HeLa, HEK-293, A-431, A549
Predicted Reactivity Ms, Rt
Purification Protein A
Concentration 2 mg/ml
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide

Stability & Storage

12 months from date of receipt / reconstitution, -20 °C as supplied

Dilution


application dilution species
WB 1:1000 Hu

Background

TAK1 (transforming growth factor-β-activated kinase 1, encoded by the MAP3K7 gene) is a widely expressed serine/threonine kinase of the MAP3K family that serves as a core integrating hub of the NF-κB and MAPK signaling pathways, playing key roles in immunity, inflammation, development, and cell survival. Structurally, it contains an N-terminal kinase domain and a C-terminal regulatory domain and requires assembly with TAK1-binding proteins (TAB1, TAB2, etc.) into a complex for efficient activation, a process involving sequential autophosphorylation of multiple activation-loop residues. TAK1 lies downstream of TNF receptor, Toll-like receptor, and IL-1 receptor signaling and regulates the NF-κB and JNK/p38 pathways by activating the IKK complex and MKK4/7 and MKK3/6, respectively. In intestinal epithelial cells, TAK1 maintains barrier integrity by restraining TNFR1-proximal death signaling, whereas in myeloid cells it can amplify inflammatory signals, displaying cell-type- and disease-stage-specific dual functions. In addition, TAK1 acts as a tumor-intrinsic immune checkpoint that protects cancer cells from CD8⁺ T cell- and cytokine-mediated killing. Clinically, gain-of-function mutations in MAP3K7 cause frontometaphyseal dysplasia and cardiospondylocarpofacial syndrome, while different mutation types can also cause developmental abnormalities such as neonatal dilated cardiomyopathy.

Picture

Western Blot

WB result of TAK1 Recombinant Rabbit mAb
Primary antibody: TAK1 Recombinant Rabbit mAb at 1/1000 dilution
Primary antibody incubation conditions: overnight at 4°C
Lane 1: HeLa whole cell lysate 20 µg
Lane 2: HEK-293 whole cell lysate 20 µg
Lane 3: A-431 whole cell lysate 20 µg
Lane 4: A549 whole cell lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 65 kDa
Observed MW: 69 kDa